Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 5/20 | 0.41 |
| ▸ | CDC7 | O00311 | 4/20 | 0.39 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.39 |
| ▸ | CIT | O14578 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053448 | 0.88 | SCN10A (0.67) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL1293368 | 0.85 | SCN10A (0.64) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL1293364 | 0.85 | SCN10A (0.64) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL16907913 | 0.85 | SCN10A (0.64) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL1293405 | 0.84 | SCN10A (0.63) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL12798837 | 0.84 | SCN10A (0.63) | SCN10APARP1CDC7NPC1RAB9A | |
| SCHEMBL1293406 | 0.84 | SCN10A (0.63) | SCN10APARP1NPC1RAB9AAAK1 | |
| SCHEMBL19385241 | 0.83 | SCN10A (0.62) | SCN10APARP1AAK1USP30NPY5R | |
| SCHEMBL19385240 | 0.83 | SCN10A (0.62) | SCN10APARP1AAK1USP30NPY5R | |
| SCHEMBL17656211 | 0.83 | SCN10A (0.65) | SCN10APARP1CDC7DYRK1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906655-B2 | 5,5'-(1,2-ethynediyl)bis(2-((2S)-1-((2R)-2-phenylpropanoyl)-2-pyrrolidinyl)-1H-benzimidazole); inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068176-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SCN10A 4625/4885PARP1 3489/4885CDC7 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.